Romulus K. Brazzell - Jun 27, 2022 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
Head of Research and Development and Chief Medical Officer
Signature
/s/ Mary Reumuth, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Jun 27, 2022
Transactions value $
-$1,163
Form type
4
Date filed
6/29/2022, 08:11 PM
Previous filing
Jan 5, 2022
Next filing
Oct 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale -$1.16K -3.14K -1.09% $0.37 285K Jun 27, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020.
F2 Includes 58,834 unvested RSUs.

Remarks:

Head of Research and Development and Chief Medical Officer